



**Suppl Fig 1: IL-2, but not anti-CD40 Ab monotherapy enhances *in vivo* CTL activity**  
 C57BL/6J mice bearing small (9 - 20 mm<sup>2</sup>) AE17-sOVA tumors were given three or six i.t. doses of PBS (n = 8 mice), IL-2 (n = 8 mice; Suppl Fig 1a) or anti-CD40 Ab (n = 8 mice; Suppl Fig 1b). Fluorescently labeled, target cells expressing MHC class I bound SIINFEKL were adoptively transferred into tumor-bearing mice and *in vivo* CTL activity was determined in the dLN and non-dLN. Pooled data shown from two experiments (24 mice per timepoint, 48 mice total) are represented as mean  $\pm$  SEM. \* =  $p < 0.05$ , n.s. = not significant comparing treated groups to PBS-treated controls.